All Oncology News

Dostarlimab/chemotherapy/niraparib elicited favorable PFS outcomes across several subgroups in primary advanced or recurrent endometrial cancer.

The financial performance of Florida Cancer Specialists & Research Institute for the first two months of 2024 surpassed the statewide practice’s budget.

The Japanese PMDA has approved first-line osimertinib plus chemotherapy for EGFR-mutated advanced non–small cell lung cancer.

China’s NMPA approved toripalimab plus nab-paclitaxel for the first-line treatment of recurrent or metastatic triple-negative breast cancer.

Adjuvant durvalumab did not improve disease-free survival in resected, early-stage non–small cell lung cancer with a PD-L1 expression 25% or more.

Perioperative durvalumab demonstrated a statistically significant improvement in EFS and OS in muscle-invasive bladder cancer.

Jorge J. Nieva, MD, details the role of telemedicine for patients with non–small cell lung cancer and a first-of-its-kind study examining atezolizumab given subcutaneously at home.

Linvoseltamab demonstrated durable efficacy with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

Robert L. Ferris, MD, PhD, has been named the executive director of UNC Lineberger Comprehensive Cancer Center and UNC system chief of oncology services.

First-line rucaparib maintenance therapy maintained a PFS benefit vs placebo at 4 years of follow-up in newly diagnosed advanced ovarian cancer.

The Ministry of Health, Labour, and Welfare in Japan has approved momelotinib for use in patients with myelofibrosis.

The FDA has approved crovalimab for patients 13 years of age and older with paroxysmal nocturnal hemoglobinuria and a body weight of at least 40 kg.

An expanded indication for dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer is under EMA review.

Valemetostat tosilate has been approved by the Japan Ministry of Health, Labor and Welfare for the treatment of patients with relapsed/refractory PTCL.

Trilaciclib plus chemotherapy failed to improve overall survival in metastatic triple-negative breast cancer.

A panel of expert clinicians discuss the treatment landscape of HER2-mutant non–small cell lung cancer, highlighting the current roles of ADCs and TKIs, and unmet needs that remain in the space.

Sid Devarakonda, MD, details the role of surgery for patients with non–small cell lung cancer and approaches for treating patients with metastatic disease.

The European Commission has approved fruquintinib for select patients with pretreated metastatic colorectal cancer.

Lauren E. Nye, MD, discusses the use of CDK4/6 inhibitors in HR-positive metastatic breast cancer and the evolution of ADCs in HER2-positive disease.

Lucio Gordan, MD, will join a panel to discuss treatment options for newly-diagnosed, transplant ineligible multiple myeloma.

Edward B. Garon, MD, MS, takes stock of the non–small cell lung cancer field in light of recent updates from clinical trials.

First-line lenvatinib plus pembrolizumab demonstrated antitumor activity across various histologic subtypes in advanced or recurrent endometrial cancer.

Durvalumab plus chemotherapy, followed by durvalumab maintenance with or without olaparib, improved responses in advanced endometrial cancer.

The FDA has approved adagrasib plus cetuximab for patients with KRAS G12C–mutant locally advanced or metastatic colorectal cancer.

Patients with leptomeningeal metastasis from HER2-positive breast cancer experienced clinical benefit with tucatinib plus trastuzumab and capecitabine.

MB-106 showcased a favorable safety profile and elicited responses in heavily pretreated patients with refractory Waldenström macroglobulinemia.

The EMA has validated an extension application for the subcutaneous formulation of nivolumab in adult patients with solid tumor indications.

Mirvetuximab soravtansine generated PFS, OS, and ORR improvements in patients with ovarian cancer who required dose modifications in the MIRASOL trial.

Three Huntsman Cancer Institute researchers have recently been recognized for their work as outstanding faculty members at the University of Utah.

Komal Jhaveri, MD, FACP, highlights the novel PI3Kα inhibitor RLY-2608 and discusses the details of the first-in-human trial of the agent.